Loading...
•
Jun 30, 2024
Carisma Therapeutics Q2 2024 Earnings Report
Carisma Therapeutics reported financial results for Q2 2024 and highlighted recent business updates.
Key Takeaways
Carisma Therapeutics reported that cash and cash equivalents are expected to fund the Company into the third quarter of 2025. Initial data for CT-0525, lead product candidate for anti-HER2 program, expected by year-end 2024. Nomination of a development candidate for liver fibrosis program expected in the first quarter of 2025.
Initial data for CT-0525, lead product candidate for anti-HER2 program, is expected by year-end 2024.
A development candidate for the liver fibrosis program is expected to be nominated in the first quarter of 2025.
The first in vivo CAR-M development candidate targeting Glypican-3 to treat hepatocellular carcinoma was nominated under the Moderna Collaboration in the second quarter of 2024.
Cash and cash equivalents of $40.4 million, along with $2.0 million received in July under the Moderna Collaboration, are expected to fund the Company into the third quarter of 2025.
Carisma Therapeutics
Carisma Therapeutics
Forward Guidance
Carisma anticipates that its cash and cash equivalents of $40.4 million as of June 30, 2024 are sufficient to sustain its planned operations into the third quarter of 2025.